TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $170 | $169 | $154 | $179 |
| Short-Term Investments | $15 | $49 | $98 | $111 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $3 | $3 | $3 |
| Total Curr. Assets | $188 | $221 | $255 | $293 |
| Property Plant & Equip (Net) | $69 | $71 | $71 | $72 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $5 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $7 | $7 | $7 |
| Total NC Assets | $74 | $77 | $78 | $78 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $262 | $299 | $333 | $371 |
| Liabilities | – | – | – | – |
| Payables | $6 | $5 | $5 | $4 |
| Short-Term Debt | $7 | $6 | $5 | $5 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $5 | $8 | $10 | $12 |
| Other Curr. Liab. | $11 | $13 | $10 | $15 |
| Total Curr. Liab. | $29 | $31 | $30 | $36 |
| LT Debt | $89 | $90 | $92 | $93 |
| Deferred Rev, NC | $0 | $0 | $1 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $89 | $91 | $93 | $94 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $56 | $64 | $65 | $65 |
| Total Liabilities | $118 | $122 | $123 | $130 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$482 | -$446 | -$409 | -$375 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $626 | $623 | $619 | $616 |
| Total Equity | $144 | $177 | $210 | $241 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $262 | $299 | $333 | $371 |
| Net Debt | -$74 | -$73 | -$57 | -$81 |